Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation.
- DOI
- 10.1080/14737167.2026.2691190
- Published
- 2026 Jul
- Container
- Expert review of pharmacoeconomics & outcomes research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737167.2026.2691190,
title = {Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation.},
author = {Tiemens A and Sauboin C and Wolters S and Bond SJ and Bentvelzen JOM and Monteiro S and Walsh S and Postma MJ},
year = {2026},
journal = {Expert review of pharmacoeconomics \& outcomes research},
doi = {10.1080/14737167.2026.2691190},
url = {https://doi.org/10.1080/14737167.2026.2691190}
}RIS
TY - JOUR TI - Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation. AU - Tiemens A AU - Sauboin C AU - Wolters S AU - Bond SJ AU - Bentvelzen JOM AU - Monteiro S AU - Walsh S AU - Postma MJ PY - 2026 JO - Expert review of pharmacoeconomics & outcomes research DO - 10.1080/14737167.2026.2691190 UR - https://doi.org/10.1080/14737167.2026.2691190 ER -
APA
A, T., C, S., S, W., SJ, B., JOM, B., S, M., S, W., & MJ, P. (2026). Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation.. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2026.2691190
Source records
- pubmed · retrieved 2026-11-10T20:33:56.968Z